CareDx, Inc. v. Natera, Inc.
Case Number:
22-1027
Court:
Nature of Suit:
830 Patent Infringement (Fed. Qst.)
Companies
Sectors & Industries:
-
December 02, 2022
Fed. Circ. Won't Rethink Axed Stanford Kidney Test Patents
The Federal Circuit on Friday declined to review en banc a panel's decision that three Stanford University diagnostic patents licensed to a developer of commercial tests for kidney transplant rejections are ineligible for protection.
-
November 15, 2022
Natera Says Fed. Circ. Panel Rightly Axed DNA Test Patents
Genetic testing company Natera has urged the full Federal Circuit not to review a panel's decision agreeing that three Stanford University diagnostic patents are ineligible for protection, arguing the panel didn't misapply a two-part patent eligibility test.
-
October 03, 2022
Ex-Fed. Circ. Chief Tells Court To Undo Ax Of Tech Patent
A former Federal Circuit chief judge has urged that appellate court to overturn a panel's decision agreeing that three of Stanford University's diagnostic patents are ineligible for protection since they're directed toward a natural phenomenon, arguing that the ruling unnecessarily forecloses patent protection for novel and nonobvious diagnostic techniques.
-
July 18, 2022
Federal Circuit Upholds Invalidation Of Kidney Test Patents
The Federal Circuit on Monday refused to undo a lower court's finding that three Stanford University patents licensed to a developer of commercial tests for kidney transplant rejections were invalid, saying they are directed toward natural phenomena.
-
June 10, 2022
Fed. Circ. Eyes Eligibility Of Stanford's Transplant Testing IP
Two Federal Circuit judges did not seem fully convinced Friday that three Stanford University patents licensed to CareDx Inc., developer of commercial tests for kidney transplant rejections, are valid under the U.S. Supreme Court's landmark Alice ruling.